Form of presentation for 3-[(2-{[4-hexyloxycarbonylamino-iminomethyl)-phenylamino]-methyl}-1-methyl1H-benzimidazol-5-carbonyl)-pyridin-2yl-amino] propionic acid ethyl ester to be administered orally

Details for Australian Patent Application No. 2003210400 (hide)

Owner Boehringer Ingelheim Pharma GmbH & Co. KG

Inventors Brauns, Ulrich; Hauel, Norbert

Agent Davies Collison Cave

Pub. Number AU-B-2003210400

PCT Number PCT/EP03/02141

PCT Pub. Number WO2003/074056

Priority 102 45 624.0 30.09.02 DE; 102 09 985.5 07.03.02 DE

Filing date 3 March 2003

Wipo publication date 16 September 2003

Acceptance publication date 7 August 2008

International Classifications

A61K 31/4439 (2006.01)

A61K 9/48 (2006.01) Medicinal preparations characterised by special physical form - Preparations in capsules, e.g. of gelatin, of chocolate

A61K 47/12 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Carboxylic acids

A61K 47/16 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - containing nitrogen

A61K 47/32 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds

A61K 47/38 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Cellulose

A61P 7/02 (2006.01) Drugs for disorders of the blood or the extracellular fluid

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

Event Publications

17 July 2003 Complete Application Filed

  Priority application(s): 102 45 624.0 30.09.02 DE; 102 09 985.5 07.03.02 DE

23 October 2003 Application Open to Public Inspection

  Published as AU-B-2003210400

7 August 2008 Application Accepted

  Published as AU-B-2003210400

4 September 2008 Corrigenda

  Applications OPI - Name Index Under the name Boehringer Ingelheim Pharma GmbH & Co. KG, Application No. 2003210400, under INID (54) correct the title to read Form of presentation for 3-[(2-{[4-hexyloxycarbonylamino-imino - methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-py ridin-2-yl-amino] propionic acid ethyl ester to be administered orally

25 September 2008 Corrigenda

  Applications Accepted - Name Index Under the name Boehringer Ingelheim Pharma GmbH & Co. KG, Application No. 2003210400, under INID (54), correct the invention title to read Form of presentation for 3-[(2-{[4-hexyloxycarbonylamino-imino - methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-py ridin-2-yl-amino] propionic acid ethyl ester to be administered orally

4 December 2008 Standard Patent Sealed

26 March 2009 Extension of Term of Standard Patents

  Boehringer Ingelheim Pharma GmbH & Co. KG The earliest first regulatory approval date provided by the patentee 24 Nov 2008 For the goods PRADAXA dabigatran etexilate (as dabigatran etexilate mesilate)

23 April 2009 Extension of Term of Standard Patents

  Boehringer Ingelheim Pharma GmbH & Co. KG The earliest first regulatory approval date provided by the patentee 24 Nov 2008 For the goods PRADAXA dabigatran etexilate (as dabigatran etexilate mesilate) Address for service in Australia: Davies Collison Cave 1 Nicholson Street Melbourne VIC 3000

24 September 2009 Extension granted

  Boehringer Ingelheim Pharma GmbH & Co. KG The earliest first regulatory approval date provided by the patentee 24 Nov 2008 For the goods PRADAXA dabigatran etexilate (as dabigatran etexilate mesilate) Extension of Term of patent pursuant to Section 77 expires on 24 Nov 2023

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003210401-DEVICE AND METHOD FOR GENERATING A PRINT IMAGE IN A LASERMARKING SYSTEM

2003210399-PROCESS FOR PREPARING OPTICALLY ACTIVE BETAAMINOCARBOXYLIC ACIDS FROM RACEMIC N-ACYLATED BETAAMINOCARBOXYLIC ACIDS